Details for Patent: 11,097,063
✉ Email this page to a colleague
Which drugs does patent 11,097,063 protect, and when does it expire?
Patent 11,097,063 protects OZEMPIC and SAXENDA and is included in two NDAs.
This patent has fifteen patent family members in thirteen countries.
Summary for Patent: 11,097,063
Title: | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Abstract: | A syringe device for ejecting a dose of a medicament, the syringe device comprising: a dose limiting mechanism arranged to interact with a dose ejecting mechanism to prevent ejection of a dose exceeding a set dose, and a safety mechanism, which is arranged such with respect to the dose ejecting mechanism that, if the dose limiting mechanism fails, the safety mechanism prevents ejection of a dose exceeding the set dose. |
Inventor(s): | Eiland; Jacob (Virum, DK), Enggaard; Christian Peter (Vejby, DK), Moeller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsvaerd, DK) |
Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
Application Number: | 16/250,620 |
Patent Claim Types: see list of patent claims | Use; Device; |
Drugs Protected by US Patent 11,097,063
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-004 | Oct 6, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-002 | Apr 9, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-003 | Mar 28, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Novo | SAXENDA | liraglutide | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,097,063
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
05016286 | Jul 27, 2005 |
International Family Members for US Patent 11,097,063
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | E447992 | ⤷ Sign Up | |||
Australia | 2006278928 | ⤷ Sign Up | |||
Brazil | PI0613926 | ⤷ Sign Up | |||
Canada | 2616248 | ⤷ Sign Up | |||
China | 101227942 | ⤷ Sign Up | |||
Germany | 602006010396 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |